#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15022	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2006	744.5	0	.	n	.	0	A69G	SNP	69	69	A	298	298	G	824	G,A	752,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15022	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2006	744.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1679	1679	T	840	T	756	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15022	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2006	744.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1413	1413	C	895	C,G	824,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15022	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2006	744.5	0	HET	.	.	.	C1269T	.	1269	1269	C	1498	1498	C	871	C,T	625,174	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27972	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	800.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1681	1681	A	934	A,G	857,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27972	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	800.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2315	2315	C	927	C,A	843,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27972	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	800.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2389	2389	A	877	A	817	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27972	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3484	800.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2941	2941	C	859	C,T	790,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	24	blaTEM	861	255	100.0	blaTEM.l15.c30.ctg.1	255	2.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	24	blaTEM	861	285	100.0	blaTEM.l15.c30.ctg.2	285	2.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2180	folP	852	852	99.88	folP.l15.c30.ctg.1	1552	139.9	0	.	p	.	0	E151K	NONSYN	451	453	GAA	905	907	AAA	220;219;217	A,G;A;A	196,3;199;197	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2180	folP	852	852	99.88	folP.l15.c30.ctg.1	1552	139.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1136	1138	AGC	248;249;248	A;G,A;C	223;223,1;221	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6338	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3251	194.3	1	SNP	p	S91F	0	.	.	271	273	TCC	561	563	TCC	224;225;229	T;C;C	205;207;209	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6338	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3251	194.3	1	SNP	p	D95N	0	.	.	283	285	GAC	573	575	GAC	232;232;233	G;A,G;C	213;213,1;215	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6338	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3251	194.3	1	SNP	p	D95G	0	.	.	283	285	GAC	573	575	GAC	232;232;233	G;A,G;C	213;213,1;215	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1824	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1221	148.5	1	SNP	p	G45D	0	.	.	133	135	GGC	428	430	GGC	225;231;229	G;G;C	202;205;202	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	846	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1042	80.7	0	.	n	.	0	A197.	DEL	197	197	A	583	583	A	218	A	203	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1583	1585	GCA	201;201;198	G;C;A,G	185;183;180,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	1	SNP	p	D86N	0	.	.	256	258	GAC	536	538	GAC	236;236;236	G;A;C	220;217;222	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	1	SNP	p	S87W	0	.	.	259	261	AGT	539	541	AGT	234;235;234	A;G;T	219;218;216	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	1	SNP	p	S87I	0	.	.	259	261	AGT	539	541	AGT	234;235;234	A;G;T	219;218;216	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	1	SNP	p	S87R	0	.	.	259	261	AGT	539	541	AGT	234;235;234	A;G;T	219;218;216	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5390	parC	2304	2304	99.78	parC.l6.c4.ctg.1	2871	187.2	1	SNP	p	S88P	0	.	.	262	264	TCC	542	544	TCC	233;235;235	T;C;C	217;217;219	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4784	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2700	176.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1641	1643	GGC	226;224;221	G;G;C	204;201;200	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1197	1199	GCA	247;246;251	G;C;A	222;221;228	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1200	1202	ATC	251;252;254	A;T;C	230;232;232	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1212	1214	GTG	261;260;260	G,A;T;G	237,1;237;234	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1212	1214	GTG	261;260;260	G,A;T;G	237,1;237;234	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1716	1718	ACC	211;211;212	A;C;C	187;192;194	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1770	1772	GCG	195;198;197	G;C,T,G;G	172;157,1,2;167	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1770	1772	GCG	195;198;197	G;C,T,G;G	172;157,1,2;167	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1893	1895	GGC	199;195;196	G;G;C	176;175;177	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1902	1904	GGC	187;185;185	G;G;C,A	168;163;164,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4330	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2395	180.4	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1920	1922	CTG	176;177;177	C,G;T;G	129,10;121;128	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6056	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	2947	204.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1534	1536	CCG	228;230;231	C;C;G	196;205;205	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2604	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1839	141.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	588	588	C	183	C	170	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	320	322	GAA	262;260;256	G;A;A	236;235;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	608	610	GAT	243;247;249	G;A;T	225;228;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	731	733	TCA	234;232;232	T;C;A	215;214;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	860	862	GTC	210;207;208	G;T;C	192;189;190	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	W257L	NONSYN	769	771	TGG	977	979	TTG	215;215;215	T;T;G	202;202;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1190	1192	GCA	247;248;249	G;C;A	224;227;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	1	SNP	p	G120K	1	.	.	358	360	AAG	566	568	AAG	236;237;237	A;A,T;G,T	220;220,1;220,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	1	SNP	p	A121D	1	.	.	361	363	GAC	569	571	GAC	236;238;237	G;A;C	219;219;220	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2818	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1465	190.7	1	SNP	p	D121N	0	.	.	361	363	GAC	569	571	GAC	236;238;237	G;A;C	219;219;220	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10782	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4916	218.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2009	2011	CAT	210;209;210	C;A;T	201;201;201	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1186	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	969	121.5	1	SNP	p	V57M	1	.	.	169	171	ATG	529	531	ATG	259;256;255	A;T;G	235;232;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
